The cannabis-cigarette study in the 2018 review did not report several important outcomes. Missing reporting should not be translated into zero adverse events, no withdrawals or a demonstrated remission result.
An abstract supplied limited information
The review included a 32-participant trial of smoked cannabis versus placebo cigarettes, available as a conference abstract. It reported disease-activity and inflammatory-marker information, but not clinical remission, clinical response, quality of life, overall adverse events or withdrawal due to adverse events.
The abstract did report no serious adverse events. That is a distinct, narrower statement than documenting an absence of all adverse events.
Absence of reporting limits the synthesis
An unreported endpoint cannot be assigned an effect estimate by assuming nothing happened. Nor can improvement in disease activity replace a missing remission endpoint. The review rated the cigarette study at high risk of bias for blinding participants and personnel, adding another reason for restraint.
The defensible interpretation
The review could describe the outcomes actually available and identify the gaps. It could not reconstruct a complete benefit-risk profile from an abstract. When a cannabis claim relies on this trial, retain its reporting limitations and historical publication status instead of treating omitted outcomes as favorable findings or merging them with the better-described capsule trial.
Related reading: why endpoint definitions matter.
Research cited
Kafil and colleagues (2018). Cannabis for the treatment of ulcerative colitis. DOI: 10.1002/14651858.CD012954.pub2.
Leave a Reply